Clinical Trial Update: Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating RAS(ON) inhibitors in patients with advanced non-small cell lung cancer harboring KRAS, NRAS, or HRAS mutations. The st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• RAS(ON) inhibitors

Snippet

Sponsor: Revolution Medicines, Inc. | Conditions: Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC | Phase 1, Phase 2 | Status: RECRUITING